Saturday, March 27, 2021 1:03:46 PM
Catchmeifyoucan, I think I remember you from this board, long ago when I used to post on iHub (just getting back to it after a long break). I've been holding ALT for ages, based originally on the hope for an intranasal flu vaccine. As good as I think that may yet be, an intranasal covid vaccine that doesn't need to be stored at ultra freezing temperatures is an absolute game changer. So far, so good with all the pre-clinical data. If this comes good, I think we have an absolute monster on our hands. No needles, no cold temps, and easy to transport and deliver to parts of the world where things are a little less modernized than here, Europe, etc. Life changing gains for ALT shareholders if AdCovid makes it through clinical trials. I've actually added more here in the $13s, even though I have so many shares from $1.50-2.50 range.
Best to you and all ALT longs
Best to you and all ALT longs
Recent ALT News
- Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026 • GlobeNewswire Inc. • 05/28/2026 03:00:00 PM
- Altimmune to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 05/27/2026 12:30:00 PM
- New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 • GlobeNewswire Inc. • 05/27/2026 12:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:15:13 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/13/2026 08:17:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 08:13:42 PM
- Altimmune shares climb after first-quarter loss beats expectations (ALT) • IH Market News • 05/13/2026 01:29:02 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • InvestorsHub NewsWire • 05/13/2026 01:00:00 PM
- Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities • GlobeNewswire Inc. • 05/13/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2026 11:34:07 AM
- Altimmune Announces First Quarter 2026 Financial Results and Business Update • GlobeNewswire Inc. • 05/13/2026 11:30:00 AM
- Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 • GlobeNewswire Inc. • 05/13/2026 11:15:00 AM
- Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 • GlobeNewswire Inc. • 05/06/2026 11:30:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/01/2026 08:36:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:23:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:20:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:18:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:16:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:13:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:11:03 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/01/2026 08:10:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 08:08:42 PM
- Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities • GlobeNewswire Inc. • 04/27/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/24/2026 08:05:27 PM
